Lunit Inc is a medical AI software company devoted to providing AI-powered total cancer care. Its products comprise of Lunit INSIGHT CXR, AI solution for Chest x-ray; Lunit INSIGHT MMG, AI solution for Mammography; Lunit SCOPE IO, AI-Powered Biomarker for Immuno-Oncology; and Lunit SCOPE PD-L1, AI Solution for PD-L1 Expression.
2013
272
LTM Revenue $40.4M
LTM EBITDA -$17.5M
$1.1B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Lunit has a last 12-month revenue of $40.4M and a last 12-month EBITDA of -$17.5M.
In the most recent fiscal year, Lunit achieved revenue of $36.9M and an EBITDA of -$42.1M.
Lunit expects next 12-month revenue of XXX   and NTM EBITDA of XXX
See Lunit valuation multiples based on analyst estimatesFY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
---|---|---|---|---|---|
Revenue | $17.1M | $36.9M | XXX | XXX | XXX |
Gross Profit | $9.4M | $17.1M | XXX | XXX | XXX |
Gross Margin | 55% | 46% | XXX | XXX | XXX |
EBITDA | -$21.1M | -$42.1M | XXX | XXX | XXX |
EBITDA Margin | -124% | -114% | XXX | XXX | XXX |
Net Profit | -$26.7M | -$25.1M | XXX | XXX | XXX |
Net Margin | -156% | -68% | XXX | XXX | XXX |
Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Lunit's stock price is KRW 53700 (or $37).
Lunit has current market cap of KRW 1.55T (or $1.1B), and EV of KRW 1.56T (or $1.1B).
See Lunit trading valuation dataEV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
---|---|---|---|---|---|---|
$1.1B | $1.1B | XXX | XXX | XXX | XXX | $-0.92 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Lunit has market cap of $1.1B and EV of $1.1B.
Lunit's trades at 26.2x LTM EV/Revenue multiple, and -60.5x LTM EBITDA.
Analysts estimate Lunit's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Lunit and 10K+ public compsFY 2024 | FY 2025E | FY 2026E | FY 2027E | |
---|---|---|---|---|
EV | $1.1B | XXX | XXX | XXX |
EV/Revenue | 28.7x | XXX | XXX | XXX |
EV/EBITDA | -25.2x | XXX | XXX | XXX |
P/E | -18.8x | XXX | XXX | XXX |
P/E/Growth | n/a | XXX | XXX | XXX |
EV/FCF | -21.5x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpLunit's NTM/LTM revenue growth is 42%
Lunit's revenue per employee for the last fiscal year averaged $0.1M, while opex per employee averaged $0.3M for the same period.
Over next 12 months, Lunit's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Lunit's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Lunit and other 10K+ public compsFY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
---|---|---|---|---|---|
Revenue Growth | 116% | XXX | XXX | XXX | XXX |
EBITDA Margin | -114% | XXX | XXX | XXX | XXX |
EBITDA Growth | 100% | XXX | XXX | XXX | XXX |
Rule of 40 (SaaS-only) | -72% | XXX | XXX | XXX | XXX |
Revenue per Employee | $0.1M | XXX | XXX | XXX | XXX |
Opex per Employee | $0.3M | XXX | XXX | XXX | XXX |
S&M Expenses to Revenue | 40% | XXX | XXX | XXX | XXX |
G&A Expenses to Revenue | 9% | XXX | XXX | XXX | XXX |
R&D Expenses to Revenue | 50% | XXX | XXX | XXX | XXX |
Opex to Revenue | 225% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
EV/Revenue | EV/EBITDA | |||||
---|---|---|---|---|---|---|
2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
Australian Clinical Labs | XXX | XXX | XXX | XXX | XXX | XXX |
Clarity Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
CurveBeam AI | XXX | XXX | XXX | XXX | XXX | XXX |
Cyclopharm | XXX | XXX | XXX | XXX | XXX | XXX |
Healius | XXX | XXX | XXX | XXX | XXX | XXX |
XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Lunit acquired XXX companies to date.
Last acquisition by Lunit was XXXXXXXX, XXXXX XXXXX XXXXXX . Lunit acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiplesAcquired Company | EV | EV/Revenue | EV/EBITDA |
---|---|---|---|
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign UpWhen was Lunit founded? | Lunit was founded in 2013. |
Where is Lunit headquartered? | Lunit is headquartered in South Korea. |
How many employees does Lunit have? | As of today, Lunit has 272 employees. |
Who is the CEO of Lunit? | Lunit's CEO is Mr. Beom-Seok Seo. |
Is Lunit publicy listed? | Yes, Lunit is a public company listed on KRX. |
What is the stock symbol of Lunit? | Lunit trades under 328130 ticker. |
When did Lunit go public? | Lunit went public in 2022. |
Who are competitors of Lunit? | Similar companies to Lunit include e.g. Australian Clinical Labs, Clarity Pharmaceuticals, CurveBeam AI, Cyclopharm. |
What is the current market cap of Lunit? | Lunit's current market cap is $1.1B |
What is the current revenue of Lunit? | Lunit's last 12-month revenue is $40.4M. |
What is the current EBITDA of Lunit? | Lunit's last 12-month EBITDA is -$17.5M. |
What is the current EV/Revenue multiple of Lunit? | Current revenue multiple of Lunit is 26.2x. |
What is the current EV/EBITDA multiple of Lunit? | Current EBITDA multiple of Lunit is -60.5x. |
What is the current revenue growth of Lunit? | Lunit revenue growth between 2023 and 2024 was 116%. |
Is Lunit profitable? | Yes, Lunit is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.